menu search

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in science advances demonstrating potent in vitro and in vivo antimicrobial activity

Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial f...

June 7, 2023, 5:15 am

Why is hoth therapeutics (hoth) stock up 83% today?

Hoth Therapeutics (NASDAQ: HOTH ) stock is rocketing higher on Tuesday thanks to the company announcing positive results from a pr...

June 6, 2023, 11:16 am

C4x discovery overcomes side-effect seen in competitor cancer drugs

C4X Discovery Holdings PLC (AIM:C4XD) has successfully completed a crucial preclinical study showing i...

June 1, 2023, 2:49 am

Dyne therapeutics: force platform poised to revolutionize gene therapy

Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orph...

May 27, 2023, 10:02 pm

Nkgen announces poster presentation at the 2023 american society of clinical oncology (asco) annual meeting

SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the developme...

May 25, 2023, 5:05 pm

Mindmed to present data on the preclinical activity of mm-402 at the american society of clinical psychopharmacology (ascp) 2023 annual meeting

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's pro...

May 24, 2023, 7:00 am

Cohbar, inc. and morphogenesis, inc. enter into definitive merger agreement to advance an innovative late-stage clinical immuno-oncology pipeline of therapies to overcome resistance to cancer immunoth

Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and pr...

May 23, 2023, 11:30 am

Voyager therapeutics presents robust, multi-species results from preclinical studies of iv-delivered, tracer™-generated novel capsids at the asgct 26th annual meeting

Oral presentation features further evaluation of second-generation capsids, demonstrating increased transduction in several brain areas across multipl...

May 18, 2023, 10:00 am

Immunic notes neuroprotective potential of vidofludimus calcium highlighted in preclinical data

Immunic Inc (NASDAQ:IMUX) has announced the publication of preclinical data highlighting the neuroprot...

May 17, 2023, 8:21 am

Locanabio presents preclinical data from its vectorized snrna exon skipping program for dmd and cas13d multi-targeting program for c9orf72 als at the american society of gene and cell therapy (asgct)

LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD di...

May 16, 2023, 10:00 am

Celldex therapeutics presents positive preclinical data from tslp/scf bispecific antibody program cdx-622 at immunology2023™

HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced prec...

May 15, 2023, 12:01 pm

Innate pharma to present iph6501 preclinical data at the eha 2023 congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced ...

May 15, 2023, 1:00 am

Immunitybio: anktiva rejection heightens financial urgency

ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladde...

May 12, 2023, 5:20 am

Harpoon therapeutics reports first quarter 2023 financial results and provides corporate update

Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical...

May 11, 2023, 8:30 pm

Reviva pharmaceuticals announces intent to file an ind for brilaroxazine in psoriasis after promising preclinical data

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mous...

May 11, 2023, 10:30 am

Context therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical...

May 11, 2023, 10:08 am

Prothena biosciences' unique approach to protein misfolding could be the future

Prothena's recent collaboration with Walgreens is expected to drive recruitment for Prothena's ongoing ASCENT-2 safety and tolerability trial of PRX01...

May 7, 2023, 2:28 am

Cellectis provides business update and reports financial results for first quarter 2023

First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-house Cellectis implements CLLS52 for the first time...

May 4, 2023, 8:30 pm

Prophase labs’ linebacker-1 cancer therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including l

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagno...

May 3, 2023, 12:30 pm


Search within

Pages Search Results: